文 献1） Akiyoshi T, Ishiuchi M, Imaoka A, Ohtani H. Variation in the inhibitory potency of terbinafine among genetic variants of CYP2D6. Drug Metabol Pharmacokinet 2015; 30(4): 321-4.2）Kang YS, Park SY, Yim CH, Kwak HS, Gajendrarao P, Krishnamoorthy N, et al. The CYP3A4*18 genotype in the cytochrome P450 3A4 gene, a rapid metabolizer of sex steroids, is associated with low bone mineral density. Clin Pharmacol Ther 2009; 85(3): 312-8.3）Dai D, Tang J, Rose R, Hodgson E, Bienstock RJ, Mohrenweiser HW, et al. Identification of variants of CYP3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifos. J Pharmacol Exp Ther 2001; 299(3): 825-31.4）Galetin A, Clarke SE, Houston JB. Multisite kinetic analysis of interactions between prototypical CYP3A4 subgroup substrates: midazolam, testosterone, and nifedipine. Drug Metab Dispos 2003; 31(9): 1108-165）Wang RW, Newton DJ, Liu N, Atkins WM, and Lu AYH. Human cytochrome P-450 3A4: in vitro drug-drug interaction patterns are substrate-dependent. Drug Metab Dispos 2000; 28(3): 360–6.8）Ishikawa Y, Akiyoshi T, Imaoka A, Ohtani H. Inactivation kinetics and residual activity of CYP3A4 after treatment with erythromycin. Biopharm Drug Dispos 2017; 38(7): 420-5.6）Hackett JC. Membrane-embedded substrate recognition by cytochrome P450 3A4. J Biol Chem 2018; 293(11): 4037-46.7）Ekroos M, Sjögren. Structural basis for ligand promiscuity in cytochrome P450 3A4. Proc Natl Acad Sci U S A 2006; 103(37): 13682-7.9）Akiyoshi T, Ito M, Murase S, Miyazaki M, Guengerich FP, Nakamura K, et al. Mechanism-based inhibition profiles of erythromycin and clarithromycin with cytochrome P450 3A4 genetic variants. Drug Metabol Pharmacokinet 2013; 28(5): 411-5.10）Yang J, Atkins WM, Isoherranen N, Paine MF, Thummel KE. Evidence of CYP3A allosterism in vivo: analysis of interaction between fluconazole and midazolam. Clin Pharmacol Ther 2012; 91(3): 442-9.11）Arendse LB, Blackburn JM. Effects of polymorphic variation on the thermostability of heterogenous populations of CYP3A4 and CYP2C9 enzymes in solution. Sci Rep 2018; 8(1): 11876.12）Yadav J, Korzekwa K, Nagar S. Improved predictions of drug-drug interactions mediated by time-dependent inhibition of CYP3A. Mol Pharm 2018; 15(5): 1979-95.13）Crowley JR, Hollenberg PF. Mechanism-based inactivation of rat liver cytochrome P4502B1 by phencyclidine and its oxidative product, the iminium ion. Drug Metab Dispos 1995; 23(8): 786–93.14）Sevrioukova IF, Poulos TL. Structural basis for regiospecific midazolam oxidation by human cytochrome P450 3A4. Proc Natl Acad Sci USA 2017; 114(3): 486-91.15）Miyazaki M, Nakamura K, Fujita Y, Guengerich FP, Horiuchi R, Yamamoto K, et al. Defective activity of recombinant cytochromes P450 3A4.2 and 3A4.16 in oxidation of midazolam, nifedipine, and testosterone. Drug Metab Dispos 2008; 36(11): 2287-91.151
元のページ ../index.html#165